BACKGROUND: Data on pneumococcal conjugate vaccine (PCV) indirect effects in low-income countries with high human immunodeficiency virus (HIV) burden are limited. We examined adult pneumococcal pneumonia incidence before and after PCV introduction in Kenya in 2011. METHODS: From 1 January 2008 to 31 December 2016, we conducted surveillance for acute respiratory infection (ARI) among ~12 000 adults (≥18 years) in western Kenya, where HIV prevalence is ~17%. ARI cases (cough or difficulty breathing or chest pain, plus temperature ≥38.0°C or oxygen saturation <90%) presenting to a clinic underwent blood culture and pneumococcal urine antigen testing (UAT). We calculated ARI incidence and adjusted for healthcare seeking. The proportion of ARI c...
INTRODUCTION:Streptococcus pneumoniae is the commonest cause of bacteremic pneumonia among HIV-infec...
BackgroundPneumococci are spread by persons with nasopharyngeal colonization, a necessary precursor ...
Summary: Background: In 2009, Gavi, the World Bank, and donors launched the pneumococcal Advance Ma...
Background:Data on pneumococcal conjugate vaccine (PCV) indirect effects in low-income countries wit...
SummaryBackgroundThe effect of 7-valent pneumococcal conjugate vaccine (PCV) in developed countries ...
BACKGROUND: Ten-valent pneumococcal conjugate vaccine (PCV10), delivered at 6, 10, and 14 weeks of a...
Background Pneumococcal conjugate vaccines (PCV) are highly protective against invasive pneumococcal...
Summary: Background: Pneumococcal conjugate vaccines (PCV) are highly protective against invasive p...
Background Ten-valent pneumococcal conjugate vaccine (PCV10), delivered at 6, 10, and 14 weeks of ag...
Background Pneumococcal conjugate vaccines (PCV) are highly protective against invasive pneumococcal...
INTRODUCTION:Africa harbours a high burden of pneumococcal disease, with associated high mortality r...
Background: Pneumococcal conjugate vaccines (PCV) are highly protective against invasive pneumococca...
BackgroundAlthough causing substantial morbidity, the burden of pneumococcal disease among older chi...
BackgroundThe population impact of pneumococcal conjugate vaccines (PCVs) depends on direct and indi...
BACKGROUND: Community-acquired pneumonia is a common cause of hospitalization among African adults, ...
INTRODUCTION:Streptococcus pneumoniae is the commonest cause of bacteremic pneumonia among HIV-infec...
BackgroundPneumococci are spread by persons with nasopharyngeal colonization, a necessary precursor ...
Summary: Background: In 2009, Gavi, the World Bank, and donors launched the pneumococcal Advance Ma...
Background:Data on pneumococcal conjugate vaccine (PCV) indirect effects in low-income countries wit...
SummaryBackgroundThe effect of 7-valent pneumococcal conjugate vaccine (PCV) in developed countries ...
BACKGROUND: Ten-valent pneumococcal conjugate vaccine (PCV10), delivered at 6, 10, and 14 weeks of a...
Background Pneumococcal conjugate vaccines (PCV) are highly protective against invasive pneumococcal...
Summary: Background: Pneumococcal conjugate vaccines (PCV) are highly protective against invasive p...
Background Ten-valent pneumococcal conjugate vaccine (PCV10), delivered at 6, 10, and 14 weeks of ag...
Background Pneumococcal conjugate vaccines (PCV) are highly protective against invasive pneumococcal...
INTRODUCTION:Africa harbours a high burden of pneumococcal disease, with associated high mortality r...
Background: Pneumococcal conjugate vaccines (PCV) are highly protective against invasive pneumococca...
BackgroundAlthough causing substantial morbidity, the burden of pneumococcal disease among older chi...
BackgroundThe population impact of pneumococcal conjugate vaccines (PCVs) depends on direct and indi...
BACKGROUND: Community-acquired pneumonia is a common cause of hospitalization among African adults, ...
INTRODUCTION:Streptococcus pneumoniae is the commonest cause of bacteremic pneumonia among HIV-infec...
BackgroundPneumococci are spread by persons with nasopharyngeal colonization, a necessary precursor ...
Summary: Background: In 2009, Gavi, the World Bank, and donors launched the pneumococcal Advance Ma...